AFM
PSTV

Anson Funds Management’s Plus Therapeutics PSTV Stock Holding History

Anson Funds Management’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-333
Closed -$428 – 87
2019
Q3 		$428 Buy
+333
New +$1.2M 0.31% 24
2016
Q3 		– Sell
-3
Closed -$1.22M – 64
2016
Q2 		$1.22M Buy
+3
New +$1.79M 0.23% 41

Other funds holding PSTV

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
EGM
Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Anson Funds Management's PSTV Position: Q4 2019 in Review

Anson Funds Management sold out of Plus Therapeutics (PSTV) in Q4 2019, closing a stake of 333 shares — an estimated $428 sold.

Anson Funds Management first reported a position in PSTV in Q2 2016 and held it in 2 quarters. The position peaked at $1.22M in Q2 2016. 9 funds tracked by Wall St. Rank hold PSTV as of Q4 2019.

  • Anson Funds Management reported no remaining Plus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Anson Funds Management sold 333 Plus Therapeutics shares in Q4 2019, an estimated $428.
  • Anson Funds Management first reported a position in Plus Therapeutics in Q2 2016 and held it in 2 quarters.
  • Anson Funds Management's Plus Therapeutics position peaked at $1.22M in Q2 2016.
  • 9 funds tracked by Wall St. Rank held Plus Therapeutics as of Q4 2019.

Based on Anson Funds Management's 13F filing for Q4 2019, filed 14 Feb 2020.